Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes.
Ergun-Longmire B, Marker J, Zeidler A, Rapaport R, Raskin P, Bode B, Schatz D, Vargas A, Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK. Ergun-Longmire B, et al. Among authors: zeidler a. Ann N Y Acad Sci. 2004 Dec;1029:260-77. doi: 10.1196/annals.1309.057. Ann N Y Acad Sci. 2004. PMID: 15681764 Clinical Trial.
The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.
Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group. Sosenko JM, et al. Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1. Diabetes Care. 2013. PMID: 23818528 Free PMC article.
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. Sosenko JM, et al. Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17. Diabetes. 2013. PMID: 23863814 Free PMC article.
Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.
Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D, Eisenbarth GS, Krischer JP, Schatz D; Diabetes Prevention Trial Type 1 Study Group. Redondo MJ, et al. Among authors: zeidler a. J Clin Endocrinol Metab. 2006 May;91(5):1705-13. doi: 10.1210/jc.2005-1695. Epub 2006 Feb 7. J Clin Endocrinol Metab. 2006. PMID: 16464953 Free article.
High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes.
Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T, Wasserfall C, Cuthbertson D, Krischer J; DPT-1 study group. Greenbaum CJ, et al. Among authors: zeidler a. Diabetologia. 2005 Jan;48(1):68-74. doi: 10.1007/s00125-004-1608-z. Epub 2004 Dec 16. Diabetologia. 2005. PMID: 15602651
Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups.
Marron MP, Raffel LJ, Garchon HJ, Jacob CO, Serrano-Rios M, Martinez Larrad MT, Teng WP, Park Y, Zhang ZX, Goldstein DR, Tao YW, Beaurain G, Bach JF, Huang HS, Luo DF, Zeidler A, Rotter JI, Yang MC, Modilevsky T, Maclaren NK, She JX. Marron MP, et al. Among authors: zeidler a. Hum Mol Genet. 1997 Aug;6(8):1275-82. doi: 10.1093/hmg/6.8.1275. Hum Mol Genet. 1997. PMID: 9259273
Different HLA haplotypes in Mexican Americans with IDDM.
Vadheim CM, Zeidler A, Rotter JI, Langbaum M, Shulman IA, Spencer MR, Costin G, Riley WJ, Maclaren NK. Vadheim CM, et al. Among authors: zeidler a. Diabetes Care. 1989 Jul-Aug;12(7):497-500. doi: 10.2337/diacare.12.7.497. Diabetes Care. 1989. PMID: 2758954
104 results